Brought to you by 
Three investors take part in Vical's $19mm RDO
28 May 2009
Executive Summary
In a registered direct offering, Federated Kaufmann Fund, Special Situations Funds, and an undisclosed backer have purchased 8.7mm shares of Vical (DNA vaccines for cancer and infections, and therapeutic growth factors for peripheral and coronary artery diseases) common stock for $2.31 apiece (a 3% premium), netting the company $19mm. The investors also received a 90-day option to buy 4.3mm shares for $2.25 each. Rodman & Renshaw was the placement agent.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Three investors take part in Vical's $19mm RDO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice